Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

被引：14
|
作者：
Drake, Charles G. [1 ]
机构：
[1] Johns Hopkins Univ, Dept Oncol, Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2012年 / 104卷 / 18期
关键词：
HOMEOSTATIC PROLIFERATION; CELLS; REJECTION; MELANOMA;
D O I：
10.1093/jnci/djs340
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1422 / 1422
页数：1
相关论文
共 50 条
  • [31] Is it time for everolimus-based combination in castration-resistant prostate cancer?
    Roviello, Giandomenico
    Ravelli, Andrea
    Barni, Sandro
    Petrelli, Fausto
    Bottini, Alberto
    Fox, Stephen B.
    Generali, Daniele
    FUTURE ONCOLOGY, 2016, 12 (16) : 1849 - 1852
  • [32] Selective Castration-resistant Prostate Cancer Photothermal Ablation With Copper Sulfide Nanoplates
    Chen, Jun
    Wang, Zhao-jie
    Zhang, Kai-le
    Xu, Yan-jun
    Chen, Zhi-gang
    Hu, Xiao-yong
    UROLOGY, 2019, 125 : 248 - 255
  • [33] Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
    Le, Thi Khanh
    Duong, Quang Hieu
    Baylot, Virginie
    Fargette, Christelle
    Baboudjian, Michael
    Colleaux, Laurence
    Taieb, David
    Rocchi, Palma
    CANCERS, 2023, 15 (20)
  • [34] Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
    Ferrari, Anna C.
    Alumkal, Joshi J.
    Stein, Mark N.
    Taplin, Mary-Ellen
    Babb, James
    Barnett, Ethan S.
    Gomez-Pinillos, Alejandro
    Liu, Xiaomei
    Moore, Dirk
    DiPaola, Robert
    Beer, Tomasz M.
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 52 - 63
  • [35] Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Jang, Albert
    Sartor, Oliver
    Barata, Pedro C.
    Paller, Channing J.
    CANCERS, 2020, 12 (11) : 1 - 14
  • [36] 20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
    Cao, Bo
    Qi, Yanfeng
    Yang, Yan
    Liu, Xichun
    Xu, Duo
    Guo, Wei
    Zhan, Yang
    Xiong, Zhenggang
    Zhang, Allen
    Wang, Alun R.
    Fu, Xueqi
    Zhang, Haitao
    Zhao, Lijing
    Gu, Jingkai
    Dong, Yan
    PLOS ONE, 2014, 9 (11):
  • [37] A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Rathkopf, Dana E.
    Picus, Joel
    Hussain, Arif
    Ellard, Susan
    Chi, Kim Nguyen
    Nydam, Thomas
    Allen-Freda, Erin
    Mishra, Kaushal Kishor
    Porro, Maria Grazia
    Scher, Howard I.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 537 - 544
  • [38] Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
    Schrader, Andres Jan
    Boegemann, Martin
    Ohlmann, Carsten-H.
    Schnoeller, Thomas J.
    Krabbe, Laura-Maria
    Hajili, Turkan
    Jentzmik, Florian
    Stoeckle, Michael
    Schrader, Mark
    Herrmann, Edwin
    Cronauer, Marcus V.
    EUROPEAN UROLOGY, 2014, 65 (01) : 30 - 36
  • [39] Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer
    Wang, Rong
    Mi, Yuanyuan
    Ni, Jiang
    Wang, Yang
    Ding, Lingwen
    Ran, Xuebin
    Sun, Qiaoyang
    Tan, Soo Yong
    Koeffler, H. Phillip
    Feng, Ninghan
    Chen, Yong Q.
    ADVANCED SCIENCE, 2024, 11 (09)
  • [40] Metabolomic Profiling identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer
    Kaushik, Akash K.
    Vareed, Shaiju K.
    Basu, Sumanta
    Putluri, Vasanta
    Putluri, Nagireddy
    Panzitt, Katrin
    Brennan, Christine A.
    Chinnaiyan, Arul M.
    Vergara, Ismael A.
    Erho, Nicholas
    Weigel, Nancy L.
    Mitsiades, Nicholas
    Shojaie, Ali
    Palapattu, Ganesh
    Michailidis, George
    Sreekumar, Arun
    JOURNAL OF PROTEOME RESEARCH, 2014, 13 (02) : 1088 - 1100
12345